Imiquad Cream (0.25gm Each)

Introduction

Imiquad (0.25gm Each) is a prescription medication that contains the active ingredient Imiquimod. It is used for the treatment of certain skin conditions.

Uses

Imiquad (0.25gm Each) is prescribed for the treatment of external genital warts (condyloma acuminata) in adults. It is also used for the treatment of actinic keratosis, a precancerous skin condition caused by sun exposure, on the face or scalp.

Dosage and Administration

The recommended dosage of Imiquad (0.25gm Each) for adults is a thin layer applied to the affected area once daily, before bedtime. The cream should be left on for approximately 6-10 hours and then washed off with mild soap and water. Treatment duration may vary depending on the condition being treated, and follow your healthcare provider’s instructions.

Mechanism of Action

Imiquimod, the active ingredient in Imiquad (0.25gm Each), belongs to a class of medications called immune response modifiers. It works by stimulating the body’s immune system to produce interferons and other substances that help fight off viral infections and abnormal skin cells. This helps to reduce the size and appearance of genital warts and actinic keratosis.

Side Effects

Common side effects of Imiquad (0.25gm Each) may include redness, itching, burning, or swelling at the application site. These effects are generally mild and temporary. However, if you experience severe or persistent irritation, blistering, or ulcers, contact your healthcare provider.

In rare cases, Imiquad (0.25gm Each) may cause more serious side effects such as flu-like symptoms, allergic reactions, or changes in skin pigmentation. If you experience any of these symptoms, seek medical attention immediately.

Drug Interactions

There are no known significant drug interactions with Imiquad (0.25gm Each). However, it is always important to inform your healthcare provider about all the medications you are taking, including prescription, over-the-counter, and herbal products, to ensure the safe and effective use of this medication.

Precautions

Before using Imiquad (0.25gm Each), inform your healthcare provider about any allergies you have, especially if you have had a previous allergic reaction to imiquimod or any other medications. Disclose any other medical conditions you have or any other medications you are taking.

Imiquad (0.25gm Each) is for external use only and should not be applied to open wounds, eyes, nostrils, mouth, or vagina. It is not recommended for use in children.

Storage

Imiquad (0.25gm Each) should be stored at room temperature, away from direct sunlight and heat sources. Keep the medication out of reach of children and pets. Do not freeze the cream.

Patient Tips

• Follow the instructions provided by your healthcare provider for the proper application of Imiquad (0.25gm Each).
• Wash your hands before and after applying the cream.
• Avoid contact with the eyes, nostrils, mouth, or vagina. If accidental contact occurs, rinse thoroughly with water.
• It is normal to experience some redness, itching, or irritation at the application site. If these symptoms become severe or persistent, consult your healthcare provider.
• Use sunscreen and protective clothing to minimize sun exposure during treatment for actinic keratosis.
• If you have any questions or concerns about your treatment, do not hesitate to reach out to your healthcare provider for guidance.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Aldara 5% Cream (Health Professionals SmPC) Available at:
• Imiquimod topical (Drugs.com) [Accessed 27 Jun. 2024] (online) Available at:
• imiquimod topical (RX) [Accessed 10 Jun. 2024] (online) Available at:
• Imiquimod Topical (MedlinePlus) [Accessed 14 Jun. 2024] (online) Available at:
• Gao J, Chen F, Fang H, Mi J, Qi Q, Yang M. Daphnetin inhibits proliferation and inflammatory response in human HaCaT keratinocytes and ameliorates imiquimod-induced psoriasis-like skin lesion in mice. Biol Res. 2020 Oct 20;53(1):48. doi: 10.1186/s40659-020-00316-0. [Accessed 13 Jun. 2024] Available at: